Eronib Erlotinib Ramucirumab
MinorIn patients with solid tumours, no clinically meaningful change was seen in how much of Ramucirumab or of Erlotinib the body was exposed to when the two were used in the approved combinations. The same held for the other drugs taken alongside it, including paclitaxel, docetaxel and irinotecan (or its active metabolite, SN-38).
Little or no effect is expected. You usually do not need to change anything, but still tell your doctor or pharmacist about every medicine you take.